Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20+ B-cell non-Hodgkin’s lymphoma - Witzig, TE; White, CA; Wiseman, GA (J Clin Oncol, 1999)